Company profile: OGT
1.1 - Company Overview
Company description
- Provider of genetics research solutions, including the RNA-based SureSeq Myeloid Fusion NGS panel to identify fusion genes in acute myeloid leukaemia using a partner-gene agnostic approach; CytoCell FISH probes to detect genetic abnormalities in various cancers for diagnosis and prognosis; and the CytoSure Comprehensive FH NGS panel to detect FH-associated CNVs and SNVs at exon-level resolution.
Products and services
- CytoCell FISH Probes: Research-grade fluorescence in situ hybridisation probes that detect genetic abnormalities in various cancer types, delivering diagnostic and prognostic insight for clinical and academic genetics research
- CytoSure Comprehensive FH Panel: Exon-level-resolution NGS panel that detects FH-associated genetic variants, including CNVs and SNVs, enabling precise identification relevant to Familial Hypercholesterolaemia research
- SureSeq Myeloid Fusion NGS Panel: RNA-based panel that identifies fusion genes in acute myeloid leukaemia, including novel and rare fusions, using a partner-gene agnostic detection approach
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to OGT
PathogenDx
HQ: United States
Website
- Description: Provider of RT-PCR and DNA microarray-based pathogen detection solutions, including assays for SARS-CoV-2 genes and variants (DetectX-Rv, DetectX-Cv), environmental SARS-CoV-2 screening (EnviroX-Rv), a UTI panel detecting 26 pathogens and 12 antibiotic resistance markers (D3 Array-UTI), and semi-quantitative fungal and bacterial assays (QuantX Fungal, QuantX Bacterial).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PathogenDx company profile →
Protea Biosciences
HQ: United States
Website
- Description: Provider of mass spectrometry standards and services, including mass spectrometry imaging via LAESI and MALDI, HGMS integrating optical microscopy and histology, and LC-MS for proteomics, metabolomics, and protein characterization, enabling direct ionization, high-resolution spatial mapping, and targeted chemical profiling across diverse sample types.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Protea Biosciences company profile →
Prellis Bio
HQ: United States
Website
- Description: Provider of holographic two-photon bioprinting and the EXIS™ platform that recreates human immunobiology in vitro using 3D-printed lymph node organoids for antibody discovery, immunogenicity evaluation, and tumor immune systems; services include fully human antibody libraries, vaccine R&D, and large 3D tissue models for disease modeling, ADME/Tox, regenerative medicine, and transplantation into animal models.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Prellis Bio company profile →
Genemed Biotechnologies
HQ: United States
Website
- Description: Provider of products aimed at improving the role of surgical pathology and personalized medicine, incorporating quality throughout.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genemed Biotechnologies company profile →
InGeneron
HQ: United States
Website
- Description: Provider of autologous, evidence-based cell therapy solutions, including the Transpose RT System to isolate regenerative cells from a patient's adipose tissue for same-day treatment of various conditions, and clinical trials evaluating such therapies for rotator cuff tendinopathy, facet joint syndrome, and wrist osteoarthritis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full InGeneron company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for OGT
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to OGT
2.2 - Growth funds investing in similar companies to OGT
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for OGT
4.2 - Public trading comparable groups for OGT
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →